Follow up in a developing country of patients with complete atrio-ventricular block

JC TANTCHOU TCHOUMI, SARA FORESTI, PIERPAOLO LUPO, RICCARDO CAPPATO, GIANFRANCO BUTERA

Abstract

Aim: The purpose of the study was to assess the incidence and survival rate of patients with complete atrio-ventricular block in the cardiac centre of St Elizabeth Catholic General Hospital, Kumbo, Cameroon.

Methods: Between 2009 and 2011, 26 patients with complete atrio-ventricular block were diagnosed at our institution. Complete atrio-ventricular block was defined as complete heart block, diagnosed by echocardiographic or electrocardiographic documentation of the dissociation between electrical activity of the atria and ventricles. Hospital charts, electrocardiograms (ECG), echocardiography and chest radiography were reviewed.

Results: The triad of symptoms that pointed to the diagnosis of complete atrio-ventricular block was mainly fatigue, shortness of breath on mild physical exertion, and dizziness. The median age at diagnosis was 65 ± 15 years. The escape rhythm showed a narrow QRS complex in 35.2% of patients, whereas wide QRS complexes were seen in 64.8%. In only 15 patients were pacemakers implanted: dual-chamber in 10 and single-chamber in five cases, depending on the availability of the pacemakers. During the observational period, five non-implanted patients died, giving a mortality rate of 45%. We recorded no deaths in patients with pacemakers.

Conclusion: In developing countries, natural selection is observed in patients with complete atrio-ventricular block. Lack of infrastructure and early detection, and financial limitations are the main problems faced in the follow up of these patients. Re-organisation of the public health system, new programmes for the prevention of cardiovascular diseases, and government subsidisation are needed in our milieu.

Keywords: complete atrio-ventricular block, follow up, cardiac centre

Over the past years, cardiac pacing has become the standard mode of therapy for heart block and its complications. The increasing use of cardiac pacemakers (PM) has been encouraged by improved and simplified techniques of permanent pacing, by the development of more dependable electrodes and pulse generators, and by increasing clinical experience and follow-up data, indicating a favourable effect on the prognosis and improved cardiovascular performance.1

Across Europe in 2005, the number of new implants of pacemakers ranged from 121 to 1134 per million, and for implantable cardiac defibrillators from 1.18 to 226 per million.2 In countries of sub-Saharan Africa, patients with complete atrio-ventricular block (CAVB) and other indications for pacing are sent home because of non-availability of facilities for pacemaker implantations, limited availability of pacemakers, and high cost of the implantation procedure. The aim of the study was to assess the incidence and survival in patients with CAVB during a period of 16 months at the cardiac centre of St Elizabeth Catholic General Hospital, Shisong, Cameroon.

Methods

CAVB was defined as a complete heart block, diagnosed by echocardiographic or electrocardiographic documentation of the dissociation between electrical activity of the atria and ventricles. Hospital charts, electrocardiogram (ECG), echocardiography and chest radiography were reviewed. We analysed X-rays for cardiomegaly, which was defined as cardiothoracic ratio > 0.5.

Between 2009 and 2011, 26 patients with complete atrio-ventricular block were diagnosed at our institution. Structural heart diseases were diagnosed as follows: eight patients had hypertensive cardiomyopathy, seven had mild mitral valve regurgitation with degenerative aetiology, five had moderate mitral valve regurgitation with post-rheumatic aetiology associated with moderate tricuspid valve regurgitation, one case had post-surgical complete atrio-ventricular block, one case had severe pulmonary artery valve stenosis, and the rest of the patients had no cardiac pathology.

Local anaesthesia was given in the left subclavicular area using 20 ml of lidocaine. The left subclavian vein was punctured and the guidewire was inserted for monocamerical pacemakers. Two punctures were performed when we intended to implant a bicameral pacemaker. A pocket was created at the left subclavian area. Through the 9 and 7 French introducers we sent, respectively, the right atrial and the right ventricular leads in the case of a bicameral pacemaker. Through the 7 French introducer we sent the ventricular lead for a monocamerical pacemaker. These introducers were observed by means of radiography.

The intra-operative parameters are reported in Table 1. These parameters were optimised three months after the implantation. The leads were anchored with silk 2.0 and the pacemaker was connected. Two layers of stitches were put in: the first, subcutaneous with vicryl 2.0 and the second, intradermic with...
vicryl 3.0. The post-surgical wound was covered with a plaster.

Being a descriptive study, the data are presented as means and standard deviation.

**Results**

Symptoms and signs that pointed to the diagnosis of CA VB are listed in Table 2. Median age at diagnosis was 65 ± 15 years. The escape rhythm showed a narrow QRS complex in 35.2% of patients, whereas a wide QRS complex was seen in 64.8%. In only 15 patients were pacemakers implanted: dual-chamber in 10 and single-chamber in five cases, depending on the payment capacity of patients. Complications observed after implantation were dislodgement of the lead in one patient, haematoma in two cases, and infection of the pocket in one case.

During the observational period, five non-implanted patients in NYHA class III died, giving a mortality rate of 45%. The six remaining patients were in NYHA class II. All the implanted patients, whereas a wide QRS complex was seen in 64.8%. In only 15 patients were pacemakers implanted: dual-chamber in 10 and single-chamber in five cases, depending on the payment capacity of patients. Complications observed after implantation were dislodgement of the lead in one patient, haematoma in two cases, and infection of the pocket in one case.

During the observational period, five non-implanted patients in NYHA class III died, giving a mortality rate of 45%. The six remaining patients were in NYHA class II. All the implanted patients, whereas a wide QRS complex was seen in 64.8%. In only 15 patients were pacemakers implanted: dual-chamber in 10 and single-chamber in five cases, depending on the payment capacity of patients. Complications observed after implantation were dislodgement of the lead in one patient, haematoma in two cases, and infection of the pocket in one case.

During the observational period, five non-implanted patients in NYHA class III died, giving a mortality rate of 45%. The six remaining patients were in NYHA class II. All the implanted patients, whereas a wide QRS complex was seen in 64.8%. In only 15 patients were pacemakers implanted: dual-chamber in 10 and single-chamber in five cases, depending on the payment capacity of patients. Complications observed after implantation were dislodgement of the lead in one patient, haematoma in two cases, and infection of the pocket in one case.

During the observational period, five non-implanted patients in NYHA class III died, giving a mortality rate of 45%. The six remaining patients were in NYHA class II. All the implanted patients, whereas a wide QRS complex was seen in 64.8%. In only 15 patients were pacemakers implanted: dual-chamber in 10 and single-chamber in five cases, depending on the payment capacity of patients. Complications observed after implantation were dislodgement of the lead in one patient, haematoma in two cases, and infection of the pocket in one case.

During the observational period, five non-implanted patients in NYHA class III died, giving a mortality rate of 45%. The six remaining patients were in NYHA class II. All the implanted patients, whereas a wide QRS complex was seen in 64.8%. In only 15 patients were pacemakers implanted: dual-chamber in 10 and single-chamber in five cases, depending on the payment capacity of patients. Complications observed after implantation were dislodgement of the lead in one patient, haematoma in two cases, and infection of the pocket in one case.

During the observational period, five non-implanted patients in NYHA class III died, giving a mortality rate of 45%. The six remaining patients were in NYHA class II. All the implanted patients, whereas a wide QRS complex was seen in 64.8%. In only 15 patients were pacemakers implanted: dual-chamber in 10 and single-chamber in five cases, depending on the payment capacity of patients. Complications observed after implantation were dislodgement of the lead in one patient, haematoma in two cases, and infection of the pocket in one case.

During the observational period, five non-implanted patients in NYHA class III died, giving a mortality rate of 45%. The six remaining patients were in NYHA class II. All the implanted patients, whereas a wide QRS complex was seen in 64.8%. In only 15 patients were pacemakers implanted: dual-chamber in 10 and single-chamber in five cases, depending on the payment capacity of patients. Complications observed after implantation were dislodgement of the lead in one patient, haematoma in two cases, and infection of the pocket in one case.

During the observational period, five non-implanted patients in NYHA class III died, giving a mortality rate of 45%. The six remaining patients were in NYHA class II. All the implanted patients, whereas a wide QRS complex was seen in 64.8%. In only 15 patients were pacemakers implanted: dual-chamber in 10 and single-chamber in five cases, depending on the payment capacity of patients. Complications observed after implantation were dislodgement of the lead in one patient, haematoma in two cases, and infection of the pocket in one case.

During the observational period, five non-implanted patients in NYHA class III died, giving a mortality rate of 45%. The six remaining patients were in NYHA class II. All the implanted patients, whereas a wide QRS complex was seen in 64.8%. In only 15 patients were pacemakers implanted: dual-chamber in 10 and single-chamber in five cases, depending on the payment capacity of patients. Complications observed after implantation were dislodgement of the lead in one patient, haematoma in two cases, and infection of the pocket in one case.

**Discussion**

Occasionally, adult patients do not have any symptoms of complete atrio-ventricular block and the diagnosis is made by detecting a slow heart rate at a routine examination. The incidence of CA VB seems to be higher in Lome than in the Shisong cardiac centre, being respectively, 1 and 2% (p < 0.02). We diagnosed few patients during the observational period, probably due to natural selection.

The mortality registered in non-implanted cases was 45%, low compare to the mortality in Togo, which was 59% (p < 0.05). In tertiary centres in sub-Saharan Africa, the main cause of death is lack of finances for the procedure. Patients with the pathology must pay before the device will be implanted, the dual-chamber pacemaker being more expensive than the single chamber, which is why in Africa in general more patients have single-chamber pacemakers.

Besides eliminating the risk of sudden death, reasons for an early PM implantation in patients with CA VB are prevention of morbidity, left ventricular dilatation and dysfunction, and mitral regurgitation. Permanent pacemakers provide effective relief of symptoms and are life-saving in patients with symptomatic heart block.

Since pacemakers are only implanted by cardiologists or cardiothoracic surgeons in tertiary hospitals, the rates of pacemaker implantation provide a readily auditable measure of tertiary healthcare. In developed countries, patients with a history of complete heart block are almost absent because of the progress in medicine orientated to early detection and treatment of the condition, whereas in developing countries with the lack of finances, infrastructures and human resources, many cases are encountered.

In this context in Africa, the re-use of pacemakers from charity organisations is a good solution; it can be carried out without increased risk to the patients, provided a proper routine for technical control and sterilisation is followed. Re-use means substantial savings, which could possibly make advanced pacemaker treatment available to all eligible patients irrespective of age. Death is not necessarily the end for heart devices. In our case, all the pacemakers we used were new.

We noted that some of our patients were asymptomatic with very wide QRS complexes, strengthening the hypothesis of natural selection. Electrophysiological and genetic studies are important to understand the mechanism of natural selection. We also found that patients with post-rheumatic heart disease were well represented in our study, causing us to suspect involvement of the conduction tissue in that pathology, as it is the case in patients with Lyme disease.

The clinical state of implanted patients improved more than that of patients without pacemakers. In developing countries, cardio-stimulation should be made a department of all cardiac
centres, since many lives are saved using pacemakers as therapy in post-surgical, paroxysmal or permanent complete atrioventricular blocks.

Conclusion

In undeveloped countries characterised by natural selection of patients with complete atrioventricular block, mortality is high. Lack of infrastructure, early detection and financial limitations are the main problems faced in the follow up of these patients. Re-organisation of the public health system, new programmes of prevention of cardiovascular diseases, and government subsidisation are needed in our milieu.

References

1. Ekpe EE, Aghaji MA, Edaigbini SA, Onwuta CN. Cardiac pacemaker treatment of heart block in Enugu a 5-year review. Niger J Med 2008; 17(1): 7–12.
2. Ector H, Vardas P, on behalf of the European Heart Rhythm Association, European Society of Cardiology. Current use of pacemakers, implantable cardioverter defibrillators, and resynchronization devices: data from the registry of the European Heart Rhythm Association. Europ Heart J 2007; Supplement I: 144–149
3. Yayeh K, Ganou K, Tchamtdja T, et al. Management of high-grade atrioventricular block in Lomé, Togo. Med Trop 2011; 71(6): 637–638.
4. Thomas MO, Oke DA, Ogumuyee EO, et al. Bravypsyching: indications and management challenges in Nigeria. Pacing Clin Electrophysiol 2007; 30(6): 761–763.
5. Millar RN. Cardiac Arrhythmia Society of South Africa 1998 survey of cardiac pacing in South Africa. Report of the working group on registries of the cardiac arrhythmia society of South Africa (CASSA). Afr Med J 2001; 91(10): 873–876.
6. Zion MM, Marchand PE, Obel IW. Long-term prognosis after cardiac pacing in atrioventricular block. Br Heart J 1973; 35: 359–364.
7. Linde CL, Bocray A, Jonsson H, et al. Re-used pacemakers – as safe as new? A retrospective case-control study. Europ Heart J 1998; 19(1): 154–157.
8. Mitka M. Death not necessarily the end for heart devices. J Am Med Assoc 2007; 297(2): 144–145.
9. Mohindra R, Pannu HS, Mohan B, Kumar N, et al. Syncope in rheumatic fever. Indian Heart J 2004; 56: 668–669.

...continued from page 532

25. Gassenmaier T, Buchner S, Birner C, et al. High-sensitive troponin I in acute cardiac conditions: implications of baseline and sequential measurements for diagnosis of myocardial infarction. Atherosclerosis 2012; 222(1): 116–122.
26. Pretertis CJ, Wilgen U, Ungerer JP. Serial cardiac troponin differences measured on four contemporary analyzers: relative differences, actual differences and reference change values compared. Clin Chim Acta 2012; 413(21–22): 1786–1791. Epub 2012 Jul 10.
27. Mueller M, Bienert M, Vafaei M, et al. Absolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome. Clin Chim Acta 2012; 58: 209–218.
28. Biener M, Mueller M, Vafaei M, et al. Comparison of a 3-hour versus a 6-hour sampling protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population. Int J Cardiol 2012 Oct 10 pii: S0167-5273(12)01243-0. doi: 10.1016/j.ijcard.2012.09.122. [Epub ahead of print].
29. Reichlin T, Schindler C, Drexler B, et al. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med 2012; 172(16): 1211–1218.
30. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or n-terminal pro-B-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 2007; 53: 2086–2096.
31. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 2010; 31: 2197–2206.
32. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biomarkers in acute coronary syndromes. Clin Chem 2007; 53: 552–574.
33. Apple FS, Pearce LA, Smith SW, Kaczmarek JM, Murakami MM. Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events. Clin Chem 2009; 55: 930–937.
34. Eggers KM, Jaffe AS, Venge P, Lindahl B. Clinical implications of the change of cardiac troponin I levels in patients with acute chest pain – an evaluation with respect to the universal definition of myocardial infarction. Clin Chim Acta 2011; 412(1–2): 91–97.
35. Bonaca M, Scrivani C, Sabatine M, et al. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol 2010; 55: 2118–2124.
36. Apple FS, Pearce LA, Smith SW, Kaczmarek JM, Murakami MM. Role of monitor- ing changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events. Clin Chem 2009; 55: 930–937.
37. Mueller M, Biener M, Vafaei M, et al. Absolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome. Clin Chem 2012; 58: 209–218.
38. Apple FS, Jesse RL, Newby LW, Wu AHB, Christenson RH, for the NACB committee members and Apple FS, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, Panteghini M, Tate J, Wu AHB, for the IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD). National Academy of Clinical Biochemistry and IFCC Committee on Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem 2007; 53: 547–551.
39. Lippi G, Cervellin G, Plebani M. Sensitive cardiac troponin T assay. N Engl J Med 2010; 362: 1242.
40. Zha Y, Jenkins MM, Brass DA, Ravago PG, Horne BD, Dean SB, Drayton N. Heterophilic antibody interference in an ultra-sensitive 3-site sandwich troponin I immunoassay. Clin Chim Acta 2008; 395: 181–182.
41. Panteghini M. Assay-related issues in the measurement of cardiac troponins. Clin Chim Acta 2009; 402: 88–93.
42. Savukoski T, Engström E, Engblom I, et al. Troponin-specific autoantibody interference in different cardiac troponin I assay configurations. Clin Chem 2012; 58(6): 1040–1048.
43. Saenger AK, Beyrau R, Braun S, et al. Multicenter analytic al evaluation of a high-sensitivity troponin T assay. Clin Chim Acta 2011; 412: 748–754.
44. Bais R. The effect of sample hemolysis on cardiac troponin I and T assays. Clin Chim Acta 2011; 362(1–2): 1357–1359.
45. Gould MJ, Wilgen U, Pretertis CJ, Ungerer JP. Probing indiscernings: contamination of cardiac troponin reagent by very high patient samples causes false-positive results. Ann Clin Biochem 2012; 49(Pt 4): 395–398.